Optimization of Psoriatic and Seronegative Rheumatoid Arthritis Patients Selection and Treatment Outcomes of Biologic Therapies.

Inclusion Criteria:

• Patients fulfilling the CASPAR classification Criteria for PsA
• Patients fulfilling the 2010 ACR/EULAR classification criteria for RA
• Clinically active arthritis, with at least one joint clinically involved;
• Subject eligible to treatment (c-or b-DMARD) as indicated by the treatingrheumatologist according to usual clinical practice
• Subjects with PsA in sustained clinical and ultrasound remission (MDA)
• Patients with PsO and arthralgia

Exclusion Criteria:

• Severe and uncontrolled infections such as sepsis and opportunistic infections.
• Patients who are currently included in any interventional clinical trial in PsA or RA.
• Patients treated with more than one biologics.
• Subjects who are impaired, incapacitated, or incapable of completing study-relatedassessments
• Subjects with active vasculitis of a major organ system, with the exception ofrheumatoid nodules.
• Subjects with current symptoms of severe, progressive, or uncontrolled renal, hepatic,hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease,whether or not related to RA or PsA and which, in the opinion of the investigator,might place a subject at unacceptable risk for participation in the study.
• Female subjects who have had a breast cancer screening that is suspicious formalignancy and in whom the possibility of malignancy cannot be reasonably excluded byadditional clinical, laboratory, or other diagnostic evaluations.
• Subjects with a history of cancer in the last 5 years, other than non-melanoma skincell cancers cured by local resection or carcinoma in situ. Existing non-melanoma skincell cancers should be removed, the lesion site healed, and residual cancer ruled outbefore administration of the study drug.
• Subjects who currently abuse drugs or alcohol.
• Subjects with evidence (as assessed by the investigator) of active or latent bacterialor viral infections at the time of potential enrollment, including subjects withevidence of human immunodeficiency virus (HIV) detected during screening.
• Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 monthsbefore the informed consent document was signed.
• Subjects who have received any live vaccines within 3 months of the anticipated firstdose of study medication.
• Subjects with any serious bacterial infection within the last 3 months, unless treatedand resolved with antibiotics, or any chronic bacterial infection (eg, chronicpyelonephritis, osteomyelitis, or bronchiectasis).
• Subjects at risk for tuberculosis (TB). Specifically excluded from this study will besubjects with a history of active TB within the last 3 years, even if it was treated;a history of active TB greater than 3 years ago, unless there is documentation thatthe prior anti-TB treatment was appropriate in duration and type; current clinical,radiographic, or laboratory evidence of active TB; and latent TB that was notsuccessfully treated (≥ 4 weeks).